Starting a GLP-1 can make the calendar feel unusually important.

After the first injection, you wonder whether your appetite should already feel different. A month later, you may be comparing pounds lost. By three months, you may be asking whether treatment is really working.

The problem is that there is no standard GLP-1 weight loss timeline that every patient should follow.

Semaglutide and tirzepatide are deliberately increased over time, individuals respond differently, and clinical trials measure average outcomes across large groups—not what one person “should” weigh on a particular Tuesday.

A more useful timeline asks what each stage can reasonably tell you.

Key takeaways

• One week is much too early to judge long-term success. Some people notice appetite or gastrointestinal changes quickly; others notice little.
• After one month, many patients are still on a starting dose. Injectable Wegovy uses 0.25 mg weekly during weeks 1–4, while Zepbound uses 2.5 mg weekly for its first four weeks.
• Three months is an important review point, but not always a final verdict. Current ADA guidance uses about 5% weight reduction after three months as a common early-response benchmark while emphasizing tolerability, other health benefits and individual circumstances.
• Slower responders can still achieve meaningful later results. In a tirzepatide analysis, 90% of participants who had lost under 5% at week 12 eventually reached at least 5% by week 72.
• By one year, the overall trajectory matters more than any single week’s loss. Major trials show that weight reduction can continue for many months before leveling off.

There is no universal GLP-1 month-by-month result

Online charts often make GLP-1 treatment look remarkably predictable:

Month one, lose this much.
Month three, lose that much.
One year, reach a particular percentage.

Clinical evidence does not support using those numbers as personal targets.

Different medications use different doses and escalation schedules. People also vary in starting weight, health conditions, eating patterns, other medications, treatment adherence and biological response.

Even the headline trial results differ. In STEP 1, adults receiving semaglutide 2.4 mg lost an average of 14.9% of starting weight at week 68. In SURMOUNT-1, average losses at week 72 were 15.0%, 19.5% and 20.9% with tirzepatide 5 mg, 10 mg and 15 mg respectively.

Those are useful population-level benchmarks—not promises.

After 1 week: pay more attention to how treatment feels than what the scale says

The first week is primarily an observation period.

Some people notice:

• less hunger;
• earlier fullness;
• less interest in snacks or cravings;
• nausea;
• constipation or diarrhea;
• almost nothing noticeable.

All of those experiences are possible.

Semaglutide has documented effects on appetite and calorie intake, and later controlled research has shown reductions in hunger and food preoccupation. But there is no validated rule saying these effects must appear during the first seven days.

The same applies to weight.

In STEP 1, average semaglutide-associated weight loss was apparent by the first scheduled post-randomization assessment at week four, then continued for many months. The trial was not designed to establish a minimum week-one result.

At one week, “I haven’t lost anything” is generally not enough information to declare treatment ineffective.

After 1 month: you may still only be getting started

This is one of the most useful expectations to establish before treatment.

For current injectable Wegovy, weeks 1–4 use 0.25 mg once weekly. Weeks 5–8 then use 0.5 mg, followed by further four-week escalation steps.

Current Zepbound treatment likewise begins with 2.5 mg weekly for four weeks. The prescribing information specifically states that 2.5 mg is an initiation dose rather than a maintenance dose. The dose then increases to 5 mg, with later 2.5 mg increases possible after at least four weeks at the current dose.

That means month-one results reflect treatment during initiation, not necessarily the eventual experience on a maintenance dose.

Some people have already lost measurable weight by this stage. Others have primarily noticed appetite changes. Some have struggled more with tolerability than with weight response.

The useful question at the first-month review is therefore less:

“Did I lose enough?”

and more:

“How am I responding, how am I tolerating treatment, and is the next dose step appropriate?”

After 3 months: the first serious progress review

Three months carries more clinical meaning.

Current ADA guidance recommends assessing effectiveness and safety at least monthly during the first three months of obesity pharmacotherapy. A weight reduction of around 5% after three months is commonly used as a marker of a meaningful early response.

But the number needs context.

Someone taking injectable Wegovy according to the standard schedule has spent:

• weeks 1–4 at 0.25 mg;
• weeks 5–8 at 0.5 mg;
• weeks 9–12 at 1 mg.

They have not yet completed the full standard escalation sequence.

Tirzepatide escalation can likewise continue beyond month three depending on the maintenance dose eventually selected.

So the three-month review should consider:

• total percentage of weight lost;
• recent direction of the weight trend;
• appetite and eating changes;
• adherence and missed doses;
• side effects;
• where the patient is in titration;
• metabolic improvements where relevant;
• treatment cost and burden.

Slow at three months does not always mean unsuccessful at six

This is particularly well illustrated by tirzepatide.

A post-hoc SURMOUNT-1 analysis looked specifically at participants who had lost less than 5% after 12 weeks. They represented 18% of the analyzed group.

Among these slower responders, 70% had reached at least 5% loss by week 24 and 90% had done so by week 72. Their average time to reaching 5% was approximately 25 weeks.

That does not justify continuing ineffective treatment indefinitely. It shows why a rigid week-12 cutoff can be misleading with medications that require lengthy titration.

Between 3 and 6 months: the treatment picture usually becomes clearer

This is often when the conversation shifts from “Am I just getting started?” to “Is this strategy producing enough benefit?”

The 2026 AHA/ACC/ADA/ASN guideline recommends reassessing inadequate GLP-1-based weight response over approximately three to six months, recognizing that newer obesity medications can continue producing substantial weight reduction well beyond the earliest treatment period.

For semaglutide, STEP 4 offers useful context. Participants completing a 20-week semaglutide run-in—16 weeks of titration followed by four weeks at 2.4 mg—had lost an average of 10.6% of their starting body weight by that point.

Again, that is a trial average rather than a target.

By this stage, however, persistent minimal response deserves a more structured review: dose, adherence, tolerability, medication source, other medications and whether another treatment strategy should be considered.

After 1 year: the question becomes long-term trajectory

By a year, someone who has tolerated treatment will generally have spent much more time at or near a maintenance dose than in initial titration.

The focus therefore shifts.

Rather than asking whether the medication has started working, the questions become:

• How much clinically meaningful weight reduction has been maintained?
• Has waist circumference changed?
• Have relevant blood pressure, glucose or lipid measures improved?
• Is the dose still tolerable?
• Is weight still falling, or has it begun to plateau?
• Is treatment affordable and practical long term?

The major obesity trials show why patience matters. Semaglutide-treated participants in STEP 1 continued losing weight until around week 60, with an average 14.9% reduction at week 68.

SURMOUNT-1 continued for 72 weeks, producing average weight reductions ranging from 15.0% to 20.9% across tirzepatide maintenance doses.

Those endpoints are somewhat later than one calendar year, so they should not be relabeled as “one-year expected weight loss.” They do show that the full treatment effect can take considerably longer than the first few months to emerge.

A plateau does not necessarily mean the medication has stopped working

Eventually, continued weight loss tends to slow.

That can feel disappointing after months of visible progress, but indefinite weight reduction is neither expected nor desirable.

In STEP 1, average semaglutide weight reached its lowest point at around week 60 rather than continuing downward indefinitely.

Once meaningful weight has been lost, maintaining that reduction may itself represent successful treatment.

Current ADA guidance describes obesity as a chronic, relapsing disease and generally recommends continued pharmacotherapy after successful weight reduction when benefits continue to outweigh treatment burden and risks.

What if your GLP-1 timeline looks completely different?

That is common.

A person who loses quickly in month one is not guaranteed to continue at that rate.

A person who loses slowly during titration is not automatically a nonresponder.

And someone whose appetite feels dramatically different may not necessarily lose more weight than someone who notices subtler appetite effects.

Clinical trials produce smooth-looking average curves because hundreds or thousands of individual experiences have been combined. Real patient curves are considerably less orderly.

This is why it is usually more useful to track multi-week trends and agreed clinical goals than to judge each injection separately.

Side effects have their own timeline

Gastrointestinal effects are particularly common during initiation and dose escalation. Current ADA guidance notes that adverse effects from obesity medications are more likely when treatment begins and when doses increase.

For many people, symptoms such as nausea are temporary.

But significant symptoms should not simply be tolerated because weight is coming off.

Current Wegovy and Zepbound labeling includes warnings for serious gastrointestinal reactions, dehydration-related kidney injury, gallbladder disease and pancreatitis. Persistent or severe abdominal pain—particularly if it radiates toward the back—requires prompt medical assessment.

The correct dose is not the one that makes you feel the sickest.

What good GLP-1 follow-up should look like

The treatment timeline is also a useful way to evaluate an online clinic.

A credible program should not simply ship medication and wait for you to ask for a refill.

Current ADA guidance recommends at least monthly assessment during the first three months, followed by continued monitoring thereafter.

Before enrolling, ask:

• How often will my progress be reviewed?
• Who decides when my dose increases?
• What happens if I cannot tolerate the next dose?
• How do you decide whether treatment is working?
• What happens if I have lost little weight by three or six months?
• Who can I contact about side effects?
• What is the plan once my weight stabilizes?
• Does follow-up continue after I reach my goal weight?

A prescription is one part of the process. Dose adjustment and ongoing reassessment are part of treatment too.

The practical takeaway

A GLP-1 timeline becomes more useful when you stop treating every milestone as a weigh-in deadline.

At one week, notice what is changing without expecting proof.

At one month, remember that treatment may still be at its starting dose.

At three months, review the trend seriously—but in the context of titration, tolerability and individual response.

At one year, look at the larger outcome: weight trajectory, health changes, side effects, treatment burden and the plan for maintenance.

GLP-1 treatment is measured in months and years, not viral before-and-after moments.

The useful question is not whether your experience perfectly matches someone else’s timeline.

It is whether your own trajectory is producing enough benefit to justify continuing the treatment plan you and your clinician have chosen.

Frequently asked questions

When does GLP-1 weight loss start?

Some people lose weight during the first month, and STEP 1 found that average semaglutide-associated loss was already apparent at the first assessment at week four. But there is no required point when every patient should begin losing weight. Both semaglutide and tirzepatide use gradual dose escalation, so early treatment does not represent the full maintenance regimen.

How much weight should I lose in the first month?

There is no evidence-based number that applies to everyone. First-month results vary substantially, and common injectable regimens are still using starting doses during this period. Clinical-trial averages should not be converted into individual monthly quotas.

What if I have lost no weight after four weeks?

That alone does not prove treatment failure. Review where you are in titration, whether appetite or eating patterns have changed, whether doses were taken correctly and whether side effects have interrupted treatment. If the pattern continues, discuss it during follow-up rather than increasing the dose independently.

How much should I lose after three months on a GLP-1?

Around 5% of starting body weight after three months is often used as a useful early-response benchmark for obesity pharmacotherapy. However, newer GLP-1-based treatments have lengthy titration schedules, and some slower responders achieve substantial later loss. Treatment response should therefore be interpreted with your clinician rather than as an automatic cutoff.

When does GLP-1 weight loss usually plateau?

There is no universal plateau date. In STEP 1, average semaglutide-associated weight loss continued until around week 60. Tirzepatide trials have likewise demonstrated continued weight reduction well beyond the first several months. A plateau after substantial loss does not automatically indicate that treatment has stopped providing benefit.

Does increasing the dose make weight loss happen faster?

Higher doses can produce greater average weight reduction in some trials, but doses are escalated gradually to balance effectiveness and tolerability. Faster-than-prescribed escalation is not an appropriate way to chase quicker results. Current labeling specifies minimum intervals between dose increases.

What happens after the first year?

For people responding well, treatment often moves toward long-term maintenance rather than an automatic stop date. Current ADA guidance generally supports continued obesity pharmacotherapy after treatment goals are achieved because stopping semaglutide or tirzepatide commonly leads to weight recurrence. The long-term plan should consider benefits, tolerability, cost and patient preferences.